

**Neuro-psychiatric manifestations in systemic lupus erythematosus: new concepts from a mono-center retrospective study**

Diane Riehl

► **To cite this version:**

Diane Riehl. Neuro-psychiatric manifestations in systemic lupus erythematosus: new concepts from a mono-center retrospective study. Human health and pathology. 2018. dumas-01985089

**HAL Id: dumas-01985089**

**<https://dumas.ccsd.cnrs.fr/dumas-01985089>**

Submitted on 17 Jan 2019

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

UNIVERSITE DE NICE SOPHIA-ANTIPOLIS

FACULTE DE MEDECINE DE NICE

---

**Neuro-psychiatric manifestations in systemic lupus erythematosus:  
new concepts from a mono-center retrospective study**

---

Thèse présentée et soutenue publiquement le 12 Septembre 2018

Par Diane RIEHL

---

**Président de jury :** Pr. Jean-Gabriel FUZIBET

**Membres du jury :** Pr. Zahir AMOURA  
Pr. Eric ROSENTHAL  
Dr. Viviane QUEYREL-MORANNE  
Dr. Saskia BRESCH

**Directrice de thèse :** Dr. Fleur COHEN-AUBART



## Liste des professeurs

### Doyen

M. BAQUÉ Patrick

### Vice-Doyen

M. BOILEAU Pasca

### Assesseurs

M. ESNAULT Vincent  
M DELLAMONICA Jean  
Mme BREUIL Véronique  
M. MARTY Pierre

### Conservateur de la bibliothèque

Mme AMSELLE Danièle

### Directrice administrative des services

Mme CALLEA Isabelle

### Doyens Honoraires

M. AYRAUD Noël  
M. RAMPAL Patrick  
M. BENCHIMOL Daniel

### Professeurs Honoraires

M ALBERTINI Marc  
M. BALAS Daniel  
M. BATT Michel  
M. BLAIVE Bruno  
M. BOQUET Patrice  
M. BOURGEON André  
M. BOUTTÉ Patrick  
M. BRUNETON Jean-Noël  
Mme BUSSIERE Françoise  
M. CAMOUS Jean-Pierre  
M. CANIVET Bertrand  
M. CASSUTO Jill-patrice  
M. CHATEL Marcel  
M. COUSSEMENT Alain  
Mme CRENESSE Dominique  
M. DAR COURT Guy  
M. DELLAMONICA Pierre  
M. DELMONT Jean  
M. DEMARD François  
M. DESNUELLE Claude  
M. DOLISI Claude  
M. FRANCO Alain  
M. FREYCHET Pierre  
M. GÉRARD Jean-Pierre  
M. GILLET Jean-Yves

M. GRELLIER Patrick  
M. GRIMAUD Dominique  
M. HARTE R Michel  
M. INGLES AKIS Jean-André  
M. JOURDAN Jacques  
M. LALANNE Claude-Michel  
M. LAMBERT Jean-Claude  
M. LAZDUNSKI Michel  
M. LEFEBVRE Jean-Claude  
M. LE FICHOUX Yves  
Mme LEBRETON Elisabeth  
M. LOUBIERE Robert  
M. MARIANI Roger  
M. MASSEYEFF René  
M. MATTEI Mathieu  
M. MOUIEL Jean  
Mme MYQUEL Martine  
M. ORTONNE Jean-Paul  
M. PRINGUEY Dominique  
M. SAUTRON Jean Baptiste  
M. SCHNEIDER Maurice  
M. TOUBOL Jacques  
M. TRAN Dinh Khiem  
M VAN OBBERGHEN Emmanuel  
M. ZIEGLER Gérard

**M.C.A. Honoraire**

Mlle ALLINE Madeleine

**M.C.U. Honoraires**

M. ARNOLD Jacques  
M. BASTERIS Bernard  
Mlle CHICHMANIAN Rose-Marie Mme  
DONZEAU Michèle  
M. EMILIOZZI Roméo  
M. FRANKEN Philippe  
M. GASTAUD Marcel  
M. GIUDICELLI Jean  
M. MAGNÉ Jacques  
Mme MEMRAN Nadine  
M. MENGUAL Raymond  
M. PHILIP Patrick  
M. POIRÉE Jean-Claude  
Mme ROURE Marie-Claire

**Professeurs Classe Exceptionnelle**

M. AMIEL Jean	Urologie (52.04)
M. BERNARDIN Gilles	Réanimation Médicale (48.02)
M. BOILEAU Pascal	Chirurgie Orthopédique et Traumatologique (50.02)
M. DAR COURT Jacques	Biophysique et Médecine Nucléaire (43.01)
M. ESNAULT Vincent	Néphrologie (52-03)
Mme EULLER-ZIEGLER Liana	Rhumatologie (50.01)
M. FENICHEL Patrick	Biologie du Développement et de la Reproduction (54.05)
M. FUZIBET Jean-Gabriel	Médecine Interne (53.01)
M. GASTAUD Pierre	Ophtalmologie (55.02)
M. GILSON Éric	Biologie Cellulaire (44.03)
M. HASSEN KHODJA Reda	Chirurgie Vasculaire (51.04)
M. HÉBUTERNE Xavier	Nutrition (44.04)
M. HOFMAN Paul	Anatomie et Cytologie Pathologiques (42.03)
Mme ICHAI Carole	Anesthésiologie et Réanimation Chirurgicale (48.01)
M. LACOUR Jean-Philippe	Dermato-Vénérologie (50.03)
M. LEFTHERIOTIS Geogres	Physiologie- médecine vasculaire
M. MARQUETTE Charles-Hugo	Pneumologie (51.01)
M. MARTY Pierre	Parasitologie et Mycologie (45.02)
M. MICHIELS Jean-François	Anatomie et Cytologie Pathologiques (42.03)
M. MOUROUX Jérôme	Chirurgie Thoracique et Cardiovasculaire (51.03)
Mme PAQUIS Véronique	Génétique (47.04)
M. PAQUIS Philippe	Neurochirurgie (49.02)
M. QUATREHOMME Géraud	Médecine Légale et Droit de la Santé (46.03)
M. RAUCOULES-AIMÉ Marc	Anesthésie et Réanimation Chirurgicale (48.01)
M. ROBERT Philippe	Psychiatrie d'Adultes (49.03)
M. SANTINI Joseph	O.R.L. (55.01)
M. THYSS Antoine	Cancérologie, Radiothérapie (47.02)
M. TRAN Albert	Hépto Gastro-entérologie (52.01)

## Professeurs Première Classe

Mme ASKENAZY-GITTARD Florence	Pédopsychiatrie (49.04)
M. BAQUÉ Patrick	Anatomie - Chirurgie Générale (42.01)
M. BARRANGER Emmanuel	Gynécologie Obstétrique (54.03)
M. BÉRARD Étienne	Pédiatrie (54.01)
Mme BLANC-PEDEUTOUR Florence	Cancérologie – Génétique (47.02)
M. BONGAIN André	Gynécologie-Obstétrique (54.03)
Mme BREUIL Véronique	Rhumatologie (50.01)
M. CASTILLO Laurent	O.R.L. (55.01)
M. DE PERETTI Fernand	Anatomie-Chirurgie Orthopédique (42.01)
M. DRICI Milou-Daniel	Pharmacologie Clinique (48.03)
M. FERRARI Émile	Cardiologie (51.02)
M. FERRERO Jean-Marc	Cancérologie ; Radiothérapie (47.02)
M. GIBELIN Pierre	Cardiologie (51.02)
M. GUGENHEIM Jean	Chirurgie Digestive (52.02)
M. HANNOUN-LEVI Jean-Michel	Cancérologie ; Radiothérapie (47.02)
M. LONJON Michel	Neurochirurgie (49.02)
M. MOUNIER Nicolas	Cancérologie, Radiothérapie (47.02)
M. PADOVANI Bernard	Radiologie et Imagerie Médicale (43.02)
M. PICHE Thierry	Gastro-entérologie (52.01)
M. PRADIER Christian	Épidémiologie, Économie de la Santé et Prévention (46.01)
Mme RAYNAUD Dominique	Hématologie (47.01)
M. ROSENTHAL Éric	Médecine Interne (53.01)
M. SCHNEIDER Stéphane	Nutrition (44.04)
M. STACCINI Pascal	Biostatistiques et Informatique Médicale (46.04)
M. THOMAS Pierre	Neurologie (49.01)

## Professeurs Deuxième Classe

Mme ALUNNI Véronique	Médecine Légale et Droit de la Santé (46.03)
M. ANTY Rodolphe	Gastro-entérologie (52.01)
M. BAHADORAN Philippe	Cytologie et Histologie (42.02)
Mme BAILLIF Stéphanie	Ophthalmologie (55.02)
M. BENIZRI Emmanuel	Chirurgie Générale (53.02)
M. BENOIT Michel	Psychiatrie (49.03)
M. BREAUD Jean	Chirurgie Infantile (54-02)
M. CARLES Michel	Anesthésiologie Réanimation (48.01)
M. CHEVALIER Nicolas	Endocrinologie, Diabète et Maladies Métaboliques (54.04)
M. CHEVALLIER Patrick	Radiologie et Imagerie Médicale (43.02)
Mme CHINETTI Giulia	Biochimie-Biologie Moléculaire (44.01)
M. CLUZEAU Thomas	Hématologie (47.01)
M. DELLAMONICA Jean	réanimation médicale (48.02)
M. DELOTTE Jérôme	Gynécologie-obstétrique (54.03)
M. FONTAINE Denys	Neurochirurgie (49.02)
M. FOURNIER Jean-Paul	Thérapeutique (48-04)
Mlle GIORDANENGO Valérie	Bactériologie-Virologie (45.01)
M. GUÉRIN Olivier	Gériatrie (48.04)

M. IANNELLI Antonio	Chirurgie Digestive (52.02)
M JEAN BAPTISTE Elixène	Chirurgie vasculaire (51.04)
M. LEVRAUT Jacques	Anesthésiologie et Réanimation Chirurgicale (48.01)
M. PASSERON Thierry	Dermato-Vénérologie (50-03)
M. ROGER Pierre-Marie	Maladies Infectieuses ; Maladies Tropicales (45.03)
M. ROHRLICH Pierre	Pédiatrie (54.01)
M. ROUX Christian	Rhumatologie (50.01)
M. RUIMY Raymond	Bactériologie-virologie (45.01)
Mme SACCONI Sabrina	Neurologie (49.01)
M. SADOUL Jean-Louis	Endocrinologie, Diabète et Maladies Métaboliques (54.04)
M. TROJANI Christophe	Chirurgie Orthopédique et Traumatologique (50.02)
M. VENISSAC Nicolas	Chirurgie Thoracique et Cardiovasculaire (51.03)

### **Professeur Des Universités**

M. HOFLIGER Philippe	Médecine Générale (53.03)
----------------------	---------------------------

### **Maitre De Conférences Des Universités**

M. DARMON David	Médecine Générale (53.03)
-----------------	---------------------------

### **Professeurs Agrégés**

Mme LANDI Rebecca	Anglais
-------------------	---------

### **Maitres De Conférences Des Universités - Praticiens Hospitaliers**

M. AMBROSETTI Damien	Cytologie et Histologie (42.02)
Mme BANNWARTH Sylvie	Génétique (47.04)
M. BENOLIEL José	Biophysique et Médecine Nucléaire (43.01)
Mme BERNARD-POMIER Ghislaine	Immunologie (47.03)
M. BRONSARD Nicolas	Anatomie Chirurgie Orthopédique et Traumatologique (42.01)
Mme BUREL-VANDENBOS Fanny	Anatomie et Cytologie pathologiques (42.03)
M. DOGLIO Alain	Bactériologie-Virologie (45.01)
M DOYEN Jérôme	Radiothérapie (47.02)
M FAVRE Guillaume	Néphrologie (52.03)
M. FOSSE Thierry	Bactériologie-Virologie-Hygiène (45.01)
M. GARRAFFO Rodolphe	Pharmacologie Fondamentale (48.03)
Mme GIOVANNINI-CHAMI Lisa	Pédiatrie (54.01)
Mme HINAULT Charlotte	Biochimie et biologie moléculaire (44.01)
M. HUMBERT Olivier	Biophysique et Médecine Nucléaire (43.01)
Mme LAMY Brigitte	Bactériologie-virologie ( 45.01)
Mme LEGROS Laurence	Hématologie et Transfusion (47.01)
Mme LONG-MIRA Elodie	Cytologie et Histologie (42.02)
Mme MAGNIÉ Marie-Noëlle	Physiologie (44.02)
Mme MOCERI Pamela	Cardiologie (51.02)
Mme MUSSO-LASSALLE Sandra	Anatomie et Cytologie pathologiques (42.03)

M. NAÏMI Mourad	Biochimie et Biologie moléculaire (44.01)
Mme POMARES Christelle	Parasitologie et mycologie (45.02)
Mme SEITZ-POLSKI barbara	Immunologie (47.03)
M. TESTA Jean	Épidémiologie Économie de la Santé et Prévention (46.01)
M. TOULON Pierre	Hématologie et Transfusion (47.01)

### **Praticien Hospitalier Universitaire**

M. DURAND Matthieu	Urologie (52.04)
M. ILIE Marius	Anatomie et Cytologie pathologiques (42.03)

### **Professeurs Associés**

M. GARDON Gilles	Médecine Générale (53.03)
Mme HURST Samia	Thérapeutique (48.04)
M. PAPA Michel	Médecine Générale (53.03)

### **Maitres De Conférences Associés**

M BALDIN Jean-Luc	Médecine Générale (53.03)
Mme CASTA Céline	Médecine Générale (53.03)
M. HOGU Nicolas	Médecine Générale (53.03)
Mme MONNIER Brigitte	Médecine Générale (53.03)

### **Professeurs Conventionnés De L'université**

M. BERTRAND François	Médecine Interne
M. BROCKER Patrice	Médecine Interne Option Gériatrie
M. CHEVALLIER Daniel	Urologie
Mme FOURNIER-MEHOUAS Manuella	Médecine Physique et Réadaptation
M. JAMBOU Patrick	Coordination prélèvements d'organes
M. ODIN Guillaume	Chirurgie maxilo-faciale
M. PEYRADE Frédéric	Onco-Hématologie
M. PICCARD Bertrand	Psychiatrie
M. QUARANTA Jean-François	Santé Publique

## **Remerciements**

### **A mon maître et Président du Jury**

*Monsieur le Professeur Jean-Gabriel Fuzibet*

Je vous remercie de me faire l'honneur de présider ce jury. Vous m'avez apporté votre soutien tout au long de mon internat et m'avez fait confiance. Soyez assuré de mon plus profond respect.

### **A ma directrice de thèse**

*Madame le Docteur Fleur Cohen-Aubart*

Je te remercie de m'avoir aidé pour ce projet. J'ai été contente de passer dans ton unité où j'ai pu voir autant de maladie d'Erdheim Chester. Ton engagement pour l'enseignement des étudiants de médecine est exemplaire.

### **A mes juges**

*Monsieur le Professeur Zahir Amoura*

Je vous remercie d'avoir accepté que je vienne dans votre service pour faire mon inter-CHU à Paris, j'en ai été honorée. Je suis touchée par votre présence dans ce jury. Soyez assuré de ma reconnaissance.

*Monsieur le Professeur Eric Rosenthal*

Je vous remercie d'avoir accepté de juger mon travail de thèse et d'avoir eu confiance en moi. Merci pour vos conseils.

*Madame le Docteur Viviane Queyrel-Morrane*

Chère Viviane, je suis honorée d'avoir été ton interne. Ce fut une magnifique rencontre humaine et médicale. Je te remercie pour toute la confiance que tu m'as accordée et pour ta disponibilité. J'aimerais devenir un médecin qui te ressemble. Un grand merci.

*Madame le Docteur Saskia Bresch*

Je te remercie de faire partie du jury de ma thèse. J'espère que tu trouveras ce travail intéressant.



Je tiens à remercier mes maîtres de stage d'internat :

- Du service de Médecine interne à l'Archet 1 au CHU de Nice :  
Dr Pierre-Yves Jeandel, Dr Nathalie Tieulié, Dr Marina Taurel, Dr Jean Castela et Dr Verena Fassbender.
- Du service de Rhumatologie à l'Archet 1 :  
Dr Christian Grisot, Dr Emilie Acquacalda et Dr Amélie Florent.
- Du service de Médecine interne d'Antibes :  
Dr Denis Quinsat et Dr Charlie Guillaumont
- Du service de Néphrologie à Pasteur 2 :  
Dr Aimèle Meftah.
- Du service de Dermatologie :  
Dr Marine Cavalié, Dr Fériel Boukari et Dr Henri Montaudié.
- Du service d'Infectiologie à l'Archet 1 :  
Dr Karine Risso, Dr Johan Courjon, Dr Elisa Demonchy et Dr Eric Cua.
- Du service de Réanimation médicale à l'Archet 1 :  
Pr Jean Dellamonica, Dr Hervé Hyvernats, et Dr Denis Doyen.
- Du service de Médecine Interne 2 à la Pitié-Salpêtrière à Paris :  
Pr Julien Haroche, Dr Miguel Hie, Dr Alexis Mathian, Dr Micheline Pha.

Je n'oublie pas mes co-internes de ma spécialité qui partagent les incertitudes et les difficultés rencontrées au cours de notre internat de médecine interne : David, Margaux, Lucas, Grégoire, Antoine, Michael, Audrey, Yanis, Julie et Sonia.

Merci aussi à Sarah Lechtman (mon premier myélogramme, c'est avec toi), Astrid Malézieux (restes comme tu es, motivée et optimiste) et Nihal Martis (tu as été très présent dès les premiers jours de mon internat).

Je tiens aussi à remercier toutes les équipes soignantes de chaque service où je suis passée pendant mon internat, de jour et de nuit (infirmières, aides-soignantes, ASH, secrétaires, kinésithérapeutes, assistantes sociales, diététiciennes, attachés de recherche clinique, cadres) et avec qui j'ai passé beaucoup de temps. Merci pour l'accueil, le soutien, les moments heureux mais aussi difficiles et tristes passés ensemble.

Merci également à mes co-internes avec qui j'ai fait un bout de mon internat : Sophie, Gabriel, Thierry, Azzam, Adrien, Pierre-Michel, Chloé, Thomas, Philippe, Lauren, Alexandre, Thibaud C., Thibaut D. et Raphaèle.

## Table of contents

<b>LISTE DES PROFESSEURS</b> .....	<b>2</b>
<b>REMERCIEMENTS</b> .....	<b>7</b>
<b>RESUME</b> .....	<b>10</b>
<b>ABBREVIATIONS</b> .....	<b>14</b>
<b>ABSTRACT</b> .....	<b>15</b>
<b>INTRODUCTION</b> .....	<b>16</b>
<b>PATIENTS AND METHODS</b> .....	<b>17</b>
PATIENT SELECTION .....	17
DATA COLLECTION .....	18
STATISTICAL ANALYSES.....	19
<b>RESULTS</b> .....	<b>19</b>
PATIENT POPULATION .....	19
DEMOGRAPHIC AND CLINICAL FEATURES .....	20
IMMUNOLOGICAL RESULTS .....	21
BIOLOGICAL AND RADIOLOGICAL RESULTS .....	21
TREATMENTS .....	21
OUTCOME OF NPSLE.....	22
<b>DISCUSSION</b> .....	<b>23</b>
<b>FIGURES</b> .....	<b>28</b>
<b>TABLES</b> .....	<b>30</b>
<b>APPENDIX</b> .....	<b>35</b>
<b>REFERENCES</b> .....	<b>36</b>
<b>SERMENT D’HIPPOCRATE</b> .....	<b>39</b>

## Résumé

**Contexte :** En 1999, l'American College of Rheumatology (ACR) a défini 19 atteintes neuro-psychiatriques au cours du lupus systémique (LS). L'objectif de l'étude était d'étudier les paramètres cliniques, immunologiques et radiologiques, ainsi que les traitements et l'évolution de patients présentant un lupus neuro-psychiatrique.

**Patients et méthodes :** Nous avons mené une étude rétrospective, dans un centre spécialisé, de 2005 à 2018. Les patients étaient classés en 4 groupes selon le mécanisme physiopathologique supposé de l'atteinte : manifestations neuro-psychiatriques associées aux anticorps anti-phospholipides (APL), manifestations neuro-psychiatriques focales, manifestations neuro-psychiatriques diffuses, et manifestations neuro-psychiatriques mixtes (diffuses et focales).

**Résultats :** 81 patients (70 femmes), d'âge médian au diagnostic de LS de 27 ans [12 - 68], étaient inclus : 28 patients (34.6%) présentaient des manifestations neuro-psychiatriques associées aux APL, 8 patients (9.9%) des manifestations focales, 30 patients (37%) des manifestations diffuses et 15 (18.5%) des manifestations mixtes. L'activité du LS estimée par le Systemic Lupus Erythematosus Activity Index 2000 (SLEDAI-2K) était significativement différente entre les groupes au moment de l'atteinte neurologique ( $p=0.0001$ ) tout comme les rechutes neurologiques et les séquelles neurologiques ( $p=0,038$  et  $p=0,01$  respectivement). Dans le groupe avec atteintes focales, 3/7 patients (43%) présentaient une rechute neurologique et 5/6 (83%) avaient des séquelles neurologiques. La corticothérapie et l'hydroxychloroquine étaient utilisés dans 91% et 95% des cas respectivement, et le cyclophosphamide dans 59% des cas.

**Conclusion :** La classification des lupus neuro-psychiatriques en 4 groupes selon le mécanisme physiopathologique supposé permet de séparer des patients ayant une présentation

clinique et une évolution distinctes. Cette classification pourrait aider à guider la prise en charge thérapeutique.

**Mots-clefs :** système nerveux central, système nerveux périphérique, lupus systémique, épilepsie, auto-anticorps.

# **Neuro-psychiatric manifestations in systemic lupus erythematosus: new concepts from a mono-center retrospective study**

**Running title:** Neuropsychiatric manifestations in lupus

Diane Riehl<sup>1</sup>, MD, Fleur Cohen Aubart<sup>1</sup>, MD, PhD, Julien Haroche<sup>1</sup>, MD, PhD, Alexis Mathian<sup>1</sup>, MD, PhD, Makoto Miyara<sup>2</sup>, MD, PhD, Micheline Pha<sup>1</sup>, MD, and Zahir Amoura<sup>1</sup>, MD, MSc,

## **Affiliations**

<sup>1</sup> Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Service de Médecine Interne 2, Centre National de Référence Maladies Systémiques Rares, Lupus et Syndrome des Anticorps Antiphospholipides, Hôpital Pitié-Salpêtrière, 75013-Paris, France

<sup>2</sup> Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Département d'immunochimie, Hôpital Pitié-Salpêtrière, 75013-Paris, France

## **Correspondence to :**

Dr. Fleur Cohen Aubart, Service de Médecine Interne 2, Hôpital Pitié-Salpêtrière, 47-83

Boulevard de l'hôpital, 75651 Paris CEDEX 13

Phone +33 1 42 17 82 42; Fax +33 1 42 16 58 04

[fleur.cohen@aphp.fr](mailto:fleur.cohen@aphp.fr)

**Keywords:** central nervous system, peripheral nervous system, systemic lupus erythematosus, psychiatric disorders, epilepsy, autoantibodies.

### **Authors contributions**

F.C.A. and Z.A. designed the study.

D.R., A.M., M.M. and F.C.A. collected the data.

D.R. and F.C.A. conducted the statistical analysis.

D.R., A.M., J.H., M.M., Z.A. and F.C.A. analyzed and interpreted the data.

D.R., Z.A. and F.C.-A. wrote the manuscript.

All authors critically reviewed and approved the final version of the manuscript.

This work did not receive any financial support.

The authors declare they have no conflicts of interest to report.

## Abbreviations

<b>ACR</b>	American College of Rheumatology
<b>AQP4</b>	Anti-aquaporine 4 antibodies
<b>ANA</b>	Anti-Nuclear Antibodies
<b>APL</b>	Antiphospholipid antibodies
<b>AZA</b>	Azathioprine
<b>CNIL</b>	Commission Nationale Informatique et Libertés
<b>CNS</b>	Central Nervous System
<b>CSF</b>	Cerebro-Spinal Fluid
<b>CS</b>	Corticosteroids
<b>CYP</b>	Cyclophosphamide
<b>dsDNA</b>	Double-stranded Deoxyribo-Nucleic Acid
<b>ELISA</b>	Enzyme-Linked Immuno-Sorbent Assay
<b>ENMG</b>	Electroneuromyogram
<b>EULAR</b>	European League Against Rheumatism
<b>HCQ</b>	Hydroxychloroquine
<b>IS</b>	Immuno-Suppressive drug
<b>IV Ig</b>	Intra-Venous Immunoglobulin
<b>LN</b>	Lupus Nephritis
<b>MMF</b>	Mycophenolate Mofetic
<b>MRI</b>	Magnetic Resonance Imaging
<b>MS</b>	Multiple Sclerosis
<b>NMDA</b>	N-Méthyl-D-Aspartate
<b>NMO-SD</b>	Neuro-Myelitis Optica-Spectrum Disorders
<b>NP</b>	Neuro-Psychiatric
<b>NPSLE</b>	Neuro-Psychiatric manifestations in Systemic Lupus Erythematosus
<b>PNS</b>	Peripheral Nervous System
<b>SLICC</b>	Systemic Lupus International Collaborating Clinics
<b>SLE</b>	Systemic Lupus Erythematosus
<b>SLEDAI- 2K</b>	Systemic Lupus Erythematosus Activity Index 20

## **Abstract**

**Background:** In 1999, the American College of Rheumatology (ACR) defined 19 syndromes of neuro-psychiatric manifestations occurring during systemic lupus erythematosus (NPSLE). The aim of this study was to describe the clinical, immunological, imaging presentations, treatments and outcomes of NPSLE 19 years later.

**Patients and methods:** We conducted a retrospective study between 2005 and 2018. Patients were classified in 4 groups: neuro-psychiatric (NP) manifestations related to antiphospholipid antibodies (APL), focal NP manifestations, diffuse NP manifestations and combined diffuse and focal NP manifestations.

**Results:** 81 patients (70 women, median age at SLE diagnosis 27 years [range: 12-68]) were included: 28 patients (34.6%) with NP manifestations related to APL, 8 patients (9.9%) with focal manifestations, 30 patients (37%) with diffuse manifestations and 15 (18.5%) with combined manifestations. Disease activity evaluated with Systemic Lupus Erythematosus Activity Index 2000 (SLEDAI-2K) was significantly different between groups ( $p=0.0001$ ). The number of neurological relapses and neurological sequelae were significantly different between groups ( $p=0.038$  and  $p=0.01$  respectively): in the focal group, 3/7 patients (43%) had neurological relapses and 5/6 (83%) had neurological sequelae. Corticosteroids and hydroxychloroquine were prescribed in 91% and 95% of patients respectively, and cyclophosphamide in 59%.

**Conclusion:** This classification of NPSLE in 4 groups based on assumed pathogenic mechanisms enables to separate patients with different clinical presentations and different outcomes. It could help to guide therapeutic care.



## Introduction

Systemic lupus erythematosus (SLE) is an autoimmune disease occurring in young adults, particularly women, and characterized by multi-systemic organ involvements. The most frequent manifestations are skin, joints, and kidneys involvements, hematological manifestations, and seritis. Neuro-psychiatric (NP) manifestations are common during SLE with a prevalence ranging from 37 to 95%, according to previous studies [1].

Neuropsychiatric SLE (**NPSLE**) refers to the neurologic syndromes of the central, peripheral, and autonomic nervous system and the psychiatric syndromes observed in patients with SLE in which other causes of neurologic manifestations have been excluded. NPSLE consists of heterogeneous clinical presentations, none of them being specific of SLE. NPSLE diagnosis requires excluding NP manifestations related to infections, treatments, atherosclerosis, metabolic abnormalities, or other neurological diseases. NPSLE can precede the onset of SLE or occur at any time during its course. Most of the time, NPSLE occurs within 2 years following SLE diagnosis [2]. The pathophysiology is not fully understood. Cerebro-spinal fluid (**CSF**) analyses and cranial magnetic resonance imaging (**MRI**) data are often normal in NPSLE patients (60 to 70% and 13 to 46% of cases, respectively), leading to diagnosis pitfalls [2]. Conversely, brain MRI may be abnormal in SLE patients without NPSLE (26 to 65% of cases) [2]. In 1999, an American College of Rheumatology (**ACR**) committee defined 19 NPSLE syndromes [3]: 12 central nervous system (**CNS**) and 7 peripheral nervous system (**PNS**) syndromes (Appendix). The CNS syndromes were defined as aseptic meningitis, acute confusional state, anxiety disorders, cerebrovascular disease, cognitive dysfunction, demyelinating syndromes, headache, movement and mood disorders, myelopathy, psychosis, and seizures. The PNS syndromes were acute inflammatory demyelinating polyradiculoneuropathy, autonomic disorders, cranial neuropathy, mononeuropathy, myasthenia, plexopathy, and polyneuropathy. However, this definition of

NPSLE has several limitations. First, it did not integrate the recent tools of inflammatory neurological diseases diagnoses, as anti-aquaporine 4 (**AQP4**) antibodies. Secondly, the heterogeneity of the 19 syndromes does not guide clinicians for treatments. Third, some NPSLE syndromes are frequent in the overall population, *e.g.* headache. Finally, the manifestations related to the 19 NPSLE as described by the ACR committee have distinct mechanisms (inflammatory, vasculopathy, others), although they are all referred to “NPSLE”.

The aim of this study was to describe the characteristics of NPSLE 19 years after the ACR classification and to study 4 phenotypes based on assumed pathogenic mechanisms. Thus, we retrospectively studied clinical, biological, imaging characteristics, treatments and outcomes in NPSLE patients from a tertiary center, and compared 4 groups based on assumed pathogenic mechanisms.

## **Patients and methods**

### **Patient selection**

Patients with NPSLE were identified through the computerized database of 1300 SLE patients seen at least once in a tertiary center, which is the French National Reference Center for SLE, using the keywords “neuro-psychiatric”, “neurologic”, and “psychiatric” between 2005 and 2018. The medical charts were retrospectively reviewed.

The inclusion criteria were the following: (1) SLE according to the 1997 revised classification ACR criteria [4] or to the Systemic Lupus International Collaborating Clinics (**SLICC**) 2012 criteria [5], (2) at least one neuro-psychiatric manifestation according to the 1999 ACR commission [3]. We excluded patients with another neurologic diagnosis (including multiple sclerosis (**MS**) and neuro-myelitis optica (**NMO**)-spectrum disorders, using the recent criteria [6,7]) or an alternative cause for neuropsychiatric manifestations (infections, treatments, atherosclerosis, metabolic abnormalities or psychiatric diseases). Additionally, we excluded patients who had NP manifestations related to cryoglobulinemia

vasculitis. The medical files were reviewed by 2 independent experts (D.R. and F.C.-A) to classify the patients. In case of discrepancy between the 2 experts, a third opinion was searched (Z.A.) and considered as the final classification. Thus, the patients were classified into 4 groups based on pathophysiological mechanism of NPSLE: a group with neuro-psychiatric manifestations usually related to antiphospholipid antibodies (**APL**) (cerebrovascular disease, seizure disorders and movement disorders), regardless of positivity of these antibodies ; a group with focal neurologic manifestations (defined as myelopathy, cranial neuropathy, plexopathy, mononeuropathy or multiplex mononeuropathy, aseptic meningitis, demyelinating syndrome), a group with diffuse neurologic manifestations (including psychosis, mood disorder, cognitive dysfunction, acute confusional state, anxiety disorder, headache, myasthenia, Guillain-Barre syndrome or acute inflammatory demyelinating polyradiculoneuropathy, autonomic disorder, and polyneuropathy); and a group including patients who had combined diffuse and focal neurologic manifestations (mixed damage).

### **Data collection**

The following data were collected: demographic characteristics, delay between the diagnosis of SLE and NPSLE, clinical characteristics of NPSLE, associated manifestations of SLE (cutaneous, articular, renal or lupus nephritis (**LN**), seritis (pericarditis and pleurisy), pulmonary, digestive, haemophagocytic lymphohistiocytosis, hemolytic anemia, lymphopenia, leukopenia, thrombocytopenia, myositis, fever and adenopathy), blood test results during NPSLE (including anti-nuclear antibodies (**ANA**), anti-double-stranded deoxyribonucleic acid (**dsDNA**) and anti-soluble antigen antibodies, complement fractions (C3, C4, and CH50), antiphospholipid antibodies), CSF analyses, cranial MRI data, electroencephalogram results, electroneuromyogram (**ENMG**) results, treatments, response to treatments (adverse events, worsening outcome or improved outcome) and outcomes. An

abnormal CSF was defined by elevated proteinorachy or aseptic meningitis. Response to treatment was defined by physicians' clinical examination which was recorded in hospital reports. Outcomes were classified as death, stay in intensive care unit, neurological sequelae (sensitive and/or motor deficiency, sphincter disorders or chronic tinnitus or persistent dizziness, secondary epilepsy, persistent cognitive dysfunction or psychomotor retardation) in clinical examination and lost to follow-up (no medical data since 3 years). Inactive NPSLE after treatment was defined by lack of clinical progression of NPSLE and biological activity of SLE (normal C3 level and decrease or absence of anti-dsDNA antibodies). The Systemic Lupus Erythematosus Activity Index 2000 (**SLEDAI-2K**) score was calculated at the time of the first flare of NPSLE according to the instructions [8], and missing data were not considered. Follow-up ended February 2018.

According to the French legislation, a **CNIL** (Commission Nationale Informatique et Libertés) declaration (MR-003) was made, and the physicians informed patients of the used data.

### **Statistical analyses**

Descriptive statistics were undertaken for continuous variables. Chi2 test was used to compare qualitative variables and Kruskal & Wallis test (Mann-Whitney test-like with 3 samples or more), a non-parametric test, was used to compare quantitative variables when appropriate. All tests were 2-sided. A p value < 0.05 was considered as statistically significant.

## **Results**

### **Patient population**

Among the 1300 SLE patients of the French National Reference Center for SLE database, 117 (9%) were classified as "NPSLE". The flow chart is detailed in the **Figure 1**. Among them, 36 were excluded because they did not meet SLE criteria: 4 had MS without

SLE, 5 had NMO-SD without SLE, 4 had cryoglobulinemia vasculitis, 3 had insufficient data, and 20 had others diagnoses. Finally, 81 patients (6%) were included: 28 patients (34.6%) in the group with neuro-psychiatric manifestations related to APL, 8 patients (9.9%) in the focal group, 30 patients (37%) in diffuse group and 15 patients (18.5%) in combined group.

### **Demographic and clinical features**

The demographic and clinical characteristics of the patients are detailed in **Table 1**. Seventy patients were women (86%). Median age at SLE diagnosis was 27 years [range: 12-68]. NPSLE occurred before 30-year-old in 43 out of 81 patients (53.1%), and before 40 years-old in 66 out of 81 patients (81.5%) (**Figure 2**).

NPSLE was the first manifestation of SLE in 39 patients (48%): 11 patients (39%) in the group related to APL, 2 patients (25%) in the focal group, 18 patients (60%) in the diffuse group and 8 patients (53%) in the mixed group. NPSLE occurred with a median time of 1 month [range: 0-263] after the diagnosis of SLE. The median number of neuro-psychiatric syndromes per patient was 2 [1-7]. The median number of neuro-psychiatric manifestations differed between the 4 groups, from 1 in focal group to 3 in diffuse and related to APL groups ( $p=0.001$ ). There were 43 patients (53%) with psychiatric manifestations and up to 25 patients (83%) in diffuse group. Concomitant extra-neuropsychiatric manifestations of SLE were detailed in **Table 1**, for example no skin manifestation in focal group and 17 skin manifestations reported in diffuse and related to APL groups (57% and 61% respectively,  $p=0.005$ ). The median number of all manifestations of SLE was significantly different in these 4 groups, and was the smallest in the focal group ( $p=0.011$ ). The median SLEDAI-2K score at the time of NPSLE was 20 [range: 0-53]. The median SLEDAI-2K at the time of NPSLE was from 3 in focal group to 22 in group related to APL ( $p=0.0001$ ). CNS syndromes were present in 76 patients (94%), PNS syndromes in 9 patients (11% of the cases), 5 patients having both PNS and CNS manifestations. Three patients (38%) of focal group had PNS

manifestations. The distribution of CNS manifestations between the group related to APL and those not related to APL including the 3 other groups is detailed in Figure 3.

The most frequent neuro-psychiatric events were headache (28 patients, 35%), psychosis (26 patients, 32%), anxiety disorder (24 patients, 30%), acute confusional state (23 patients, 28%) and mood disorder (21 patients, 26%). Aseptic meningitis was associated with another neuro-psychiatric event in 15 out of 17 patients (88% of cases;  $p=0.000002$ ). Myelopathy were recorded in 5 patients (63%) of the cases of focal group, covering only 15% of all patients included ( $p=0.00002$ ).

### **Immunological results**

Positive ANA titers were found in 100% of cases, and anti-dsDNA antibodies were found in 69 patients (85%) (**Table 2**). Positive anti-ribosomal P antibodies titers were present in 9 patients (11%), never in the focal group, in 13% of the cases in diffuse and combined groups and in 11% of the cases with relationship with APL. Five patients (56%) with positive anti-ribosomal P antibodies titers had psychosis. Overall, APL titers were positive in 27 patients (34%) and APL syndrome was defined in 6 patients (7%).

### **Biological and radiological results**

Overall, CSF and brain MRI were normal in 29 patients out of 61 (48%) and in 23 out of 73 patients (32%), respectively. The CSF was normal in 16 patients (70%) in the diffuse group while it was abnormal in 12 patients (80%) in the mixed group ( $p=0.02$ ).

### **Treatments**

Hydroxychloroquine (**HCQ**) and corticosteroids (**CS**) were used in 95% and 91% of patients, respectively. CS were given without immunosuppressive drug in 11 patients (14%). Immunosuppressive drugs, which were given mostly for NPSLE, were: cyclophosphamide (**CYP**) in 48 patients (59%), mycophenolate mofetil (**MMF**) in 36 patients (44%) and azathioprine (**AZA**) in 21 patients (26%). CYP was used in 22 patients (73%) in the group

with diffuse damage, in 3 patients (38%) in the group with focal damage, in 7 patients (47%) in the group with combined damage and to 16 patients (57%) in the group with manifestations related to APL. AZA was the first-choice immunosuppressive drug used in the focal group (4 patients, 50%). Plasma exchanges were used in 18 patients (22%): 10 patients (33%) with diffuse events, 11 patients (42%) with psychosis, 8 patients (36%) with mood disorder, 6 patients (30%) with acute confusional state and 8 patients (29%) with headache (Table 3). Four patients (5%) received IV Ig: 2 patients with an acute inflammatory demyelinating polyradiculoneuropathy, one patient with chorea and one patient who had an APL syndrome and a contraindication to carry on plasma exchanges because of infection.

Fifteen patients (19%) had renal impairment associated with NPSLE, which required an immunosuppressive treatment (MMF or CYP) too, 59 patients (73%) had received an immunosuppressive drug exclusively for NPSLE (none extra-neuropsychiatric manifestations of SLE associated), as it was for 7 patients out of 8 in focal group (88%).

Finally, immunosuppressive drugs associated to HCQ and CS were used in 59 patients (72.8%). CS were efficacious in 40 out of 43 patients (93% of cases) and CYC in 27 out of 28 patients (96.4% of case). Treatments according to CNS events are described in Table 3.

### **Outcome of NPSLE**

Evolution after treatment of NPSLE is presented in Table 4. Thirty-two patients (40% of the cases) were lost to follow-up in the study. Overall, 11 patients out of 66 (17%) relapsed: 9 neurological relapses (82%) and 2 psychiatric relapses (18%). These 4 groups differed significantly about neurological relapses ( $p=0.038$ ) and neurological sequelae in clinical examination ( $p=0.01$ ): patients had the most of neurological relapses (43%) and the most neurological sequelae (83%) in the focal group.

Six patients (20%) in diffuse group and 10 patients (36%) in the group related to APL were hospitalized in intensive care unit, whereas none patient in focal group and only 2 patients (13%) in mixed group were hospitalized in intensive care unit.

Two patients died of NPSLE (multi-system organ failures): one in diffuse group and one in group related to APL.

We recorded that neuro-psychiatric conditions improved in 45 out of 48 patients (94%). At last visit, NPSLE was inactive in overall 42 out of 47 patients (89% of the cases), in 16 out of 19 patients (84% of the cases) for diffuse group, in 100% of the cases for focal group, in 5 out of 6 patients (83%) for combined group and in 15 out of 16 patients (94%) for group related to APL.

Adverse events were reported in 4 patients (5%), including 3 with infections.

## **Discussion**

In this study, we found that NPSLE can be classified in 4 groups based on assumed pathogenic mechanisms. These groups are significantly different for the disease activity ( $p=0,0001$ ), CSF abnormalities ( $p=0.02$ ), skin manifestations ( $p=0.005$ ), neurological relapses ( $p=0.038$ ) and neurological sequelae ( $p=0.01$ ). Patients with diffuse manifestations and those with manifestations related to APL appeared to have a more severe activity of extra neurologic SLE than those in focal group.

In this study, we used a classification of 4 groups of NPSLE, instead of 19 neurological syndromes. These 4 groups were based on pathogenic mechanisms. Indeed, different pathologic mechanisms were suspected [9]: inflammatory, vasculitic, and ischemic (with or without the role of APL) mechanisms. Inflammation would be mediated by injury with increased permeability of the blood-brain-barrier, involvement of intrathecal autoantibodies and immune complexes and production of inflammatory mediators (interferon alpha in particular) leading to diffuse NP manifestations [10]. This matched the diffuse group



in our study. Autoantibodies could play a role in mediating both ischemic and inflammatory disease mechanisms [9]. The anti-N-Méthyl-D-Aspartate (**NMDA**) receptors [11] and anti-ribosomal P antibodies may be involved in inflammatory mechanisms. The role of NMDA receptors was not well-defined, SLE antibodies could cross-react with DNA and NMDA receptors, gain access to CSF and mediate non-thrombotic and non-vasculitic abnormalities of the CNS [11]. Ischemic mechanisms were often caused by APL mediated by thrombosis, that is why we had classified all patients having NP events usually associated with APL in the same group regardless of their positivity. Besides, Govoni *et al.* [12] reported that APL antibodies were strongly associated with NP involvements during SLE. We assumed that in focal group the pathologic mechanism was the vasculopathy. However, Hanly *et al.* [9] proposed the hypothesis that ischemic injury mediated by APL, immune complexes and complement activation led to focal NP events (*e.g.* stroke) and diffuse NP events (*e.g.* cognitive dysfunction). Thus, it was needed to study precisely pathologic pathway with advances in neuro-imaging and use of specific biomarkers.

Similarly to previous studies, we found that headache was the most frequent NP manifestations in SLE [13,14,15]. Headache was not specific of SLE, not related to disease activity and not more frequent than in the overall population [16,17,18]. European League Against Rheumatism (**EULAR**) experts estimated the prevalence of headache between 10 and 20% [19], it varied from 3 %, in a Chinese cohort in which headache was infrequently reported since this population was known to report a lower rate of headache [20], to 87 % [21].

The anti-ribosomal P antibodies were associated with psychosis attributed to SLE [22]. In our study, 56% of patients having these antibodies had psychosis. Moreover, NPSLE was found to be associated with anti-ribosomal P antibodies and lupus anticoagulant [23].

This suggested that there were different autoimmune pathogenic mechanisms, although low sensitivity of these antibodies limited their clinical application.

Thirty-three patients were excluded in our study after review of medical files because they did not meet SLE criteria even if they were classified as “NPSLE” at first. Ainala *et al.* [24] proposed to revise NPSLE criteria excluding the syndromes without neuronal damages evidence. It resulted in an improved specificity (93%). They also excluded anxiety and headache, as well as mild depression, mild cognitive dysfunction (with deficits in fewer than 3 dimensions) and polyneuropathy unconfirmed by ENMG. Moreover, Bortoluzzi *et al.* [25] have developed a new algorithm for attribution of NP events in SLE taking into account the time onset of NP events (it was the time of appearance of the NP events with respect to the time onset of SLE: before (>6 months), concomitant (within 6 months) or after, the presence or absence of minor or not specific NP events as defined by Ainala *et al.* [24], the presence (absent, at least one and more than one) of confounding factors (*i.e.* associations as suggested by the 1999 ACR glossary) and favoring factors (not covered by the 1999 ACR classification [3], added and included both the specific SLE-related risk factors reported in the EULAR recommendations [19] and further information considered relevant for the attribution process by the expert panel). Thus, the optimal cut-off score to classify a NP event as related to SLE was higher than 7 and less than 3 to classify it as not related to SLE, with a positive predictive value of 100% and 86.3% in the training and validating cohorts, respectively. This algorithm will can be a useful tool to assist the clinician in attribution of NP events in SLE.

The CSF and brain MRI were not always abnormal in NPSLE [2, 3,19], we had the same results. Moreover, both asymptomatic patients (64.3%) and patients with neuropsychiatric manifestations (73.3%) had involvement of the CNS on brain MRI [26]. Lacking validated biomarkers and cerebral neuroimaging for an accurate attribution of the NP events occurring during the course of SLE, the clinical judgment of trained clinicians remains

the most reliable tool [10, 27, 28]. The association of clinical characterization, specific and non-invasive biomarkers and neuro-imaging could be a help to diagnose more easily NPSLE and to treat it [9, 29]. Several different magnetic resonance imaging techniques have identified microstructural or functional abnormalities. They used to determine central nervous system involvement in systemic lupus erythematosus [30].

Our study presented some limitations. First, it was a retrospective study, we also had several missing data. Probably, the prevalence of NPSLE and adverse events were underestimated since the data collection was declarative. The prevalence of NPSLE has been reported to range from 37% to over 95% [1]. It may be over-estimated, involving an over-treatment in some patients. We had only 6% of NPSLE, however this study was not designed to evaluate the prevalence of NPSLE. If isolated headache, anxiety, mild depression (no criteria for major depressive-like episodes), mild cognitive impairment (deficits in less than 3 of 8 specified cognitive domains) and polyneuropathy without electrophysiological confirmation, were not attributed to SLE, this prevalence ranged only between 19% and 38% [31]. Thus, NP events affected 6% to 12% of newly diagnosed SLE patients in the first year of disease [13], whereas we had 48% of inaugural NPSLE without these restrictions. Second, according cognitive dysfunction, formal neuro-psychological assessments were not performed on mostly patients. CSF analysis was not always done when the NP events affected only the PNS. Third, we noticed a lack of power about the focal group (only 8 patients), not enabling to conclude for some results. Next, we had an important number of lost to follow-up (40% of the cases), the patients preferring to follow-up near home. Finally, treatments are empiric and inhomogeneous, based on the knowledge about effective treatments of other serious organ damages in SLE (*e.g.* LN). We had not significant results about treatments, CYP and MMF were the more prescribed IS. In the group related to APL, 57% of patients have received CYP and 73% of patients have received it in diffuse group, we probably had an aggressive care in


our unit. Studies [32,33] showed that CYP was more effective in reducing symptoms of NP involvement in SLE compared with methylprednisolone. Besides, a low dose of intravenous CYP (200-400 mg per month) seemed to be also effective in NPSLE versus CS [34].

Catatonia was treated by plasma exchanges as it has been proposed by Marra *et al.* [35].


In conclusion, the NPSLE syndromes as defined by the ACR classification are heterogeneous and encompass a broad spectrum of pathogenic mechanisms. We showed that with a 4 groups classification based on suspected pathogenic mechanisms, we could define different clinical and outcomes profiles of patients. After confirmation of these results by replication cohorts and after studying pathogenic mechanisms of these 4 groups, this classification could help to use targeted therapies and to follow up patients according to pathogenic mechanisms.

## Figures


**Figure 1. Flow chart**



**Figure 2. Age at NP manifestations of SLE by decile and sex**



**Figure 3. Distribution of CNS manifestations between the group related to APL and those not related to APL**



Manifestations related to APL

- No
- Yes

## Tables

**Table 1. Demographic and clinical characteristics of patients with neuro-psychiatric systemic lupus erythematosus**

Abbreviations: APL, antiphospholipid antibodies; NPSLE, Neuro-Psychiatric manifestations in Systemic Lupus Erythematosus; SLE, Systemic Lupus Erythematosus; SLEDAI, Systemic Lupus Erythematosus Activity Index. All manifestations of SLE: cutaneous, articular, renal, seritis (pericarditis and pleurisy), pulmonary, digestive, haematological (haemophagocytic lymphohistiocytosis, hemolytic anemia, lymphopenia, leukopenia and thrombocytopenia), myositis, fever and adenopathy. Mixed damages: diffuse and focal damages.

	All (n=81)	Diffuse damage (n=30)	Focal damage (n=8)	Mixed damages (n=15)	Related to APL (n=28)	P
<b>Female</b>	70 (86%)	26 (87%)	8 (100%)	11 (73%)	25 (89%)	0.303
<b>Median age at SLE diagnosis (years) [range]</b>	27 [12-68]	24.5 [13-55]	27.5 [15-49]	30 [16-68]	25 [12-48]	0.711
<b>Median delay between SLE and NPSLE (months) [range]</b>	1 [0-263]	0 [0-189]	88 [0-263]	0 [0-120]	1 [0-200]	0.060
<b>Inaugural NPSLE n (%)</b>	39 (48%)	18 (60%)	2 (25%)	8 (53%)	11 (39%)	0.217
<b>Median number of all manifestations of SLE</b>	3	3	1	2	3	0.011
<b>Median number of neuro- psychiatric manifestations</b>	2	3	1	3	2.5	0.001
<b>Neurological manifestations</b>	70 (86%)	19 (63%)	8 (100%)	15 (100%)	28 (100%)	0.00008
<b>Psychiatric manifestations</b>	43 (53%)	25 (83%)	0 (0%)	6 (40%)	12 (43%)	0.00006
<b>Median SLEDAI at the time of NPSLE</b>	20	18	3	18	22	0.0001
<b>Skin manifestations</b>	38 (47%)	17 (57%)	0 (0%)	4 (27%)	17 (61%)	0.005
<b>Arthritis</b>	34 (42%)	15 (50%)	3 (38%)	5 (33%)	11 (39%)	0.705
<b>Lupus nephritis</b>	21 (26%)	10 (33%)	1 (13%)	2 (13%)	8 (29%)	0.400
<b>Pericarditis</b>	11 (14%)	5 (17%)	0 (0%)	1 (7%)	5 (18%)	0.467
<b>Seritis</b>	13 (16%)	6 (20%)	0 (0%)	1 (7%)	6 (21%)	0.326

<b>Antiphospholipid antibody syndrome</b>	6 (7%)	1 (3%)	0 (0%)	2 (13%)	3 (11%)	0.461
<b>Hemolytic anemia</b>	8 (10%)	3 (10%)	0 (0%)	0 (0%)	5 (18%)	0.210
<b>Haemophagocytic lymphohistiocytosis</b>	10 (12%)	3 (10%)	0 (0%)	2 (13%)	5 (18%)	0.556
<b>Peripheral nervous system (=PNS)</b>	9 (11%)	2 (7%)	3 (38%)	2 (13%)	2 (7%)	0.080
<b>Guillain-Barre syndrome</b>	2 (2%)	2 (7%)	0 (0%)	0 (0%)	0 (0%)	0.323
<b>Autonomic disorder</b>	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	/
<b>Mononeuropathy</b>	2 (2%)	0 (0%)	2 (25%)	0 (0%)	0 (0%)	0.0003
<b>Myasthenia</b>	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	/
<b>Cranial neuropathy</b>	5 (6%)	0 (0%)	1 (13%)	2 (13%)	2 (7%)	0.272
<b>Polyneuropathy</b>	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	/
<b>Plexopathy</b>	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	/
<b>Central nervous system (= CNS)</b>	76 (94%)	28 (93%)	5 (63%)	15 (100%)	28 (100%)	0.001
<b>Aseptic meningitis</b>	17 (21%)	0 (0%)	0 (0%)	10 (67%)	7 (26%)	0.000002
<b>Cerebrovascular disease</b>	13 (16%)	0 (0%)	0 (0%)	0 (0%)	13 (46%)	0.000002
<b>Demyelinative syndrome</b>	1 (1%)	0 (0%)	0 (0%)	1 (7%)	0 (0%)	0.216
<b>Headache</b>	28 (35%)	9 (30%)	0 (0%)	8 (53%)	11 (39%)	0.068
<b>Seizure disorder</b>	15 (19%)	0 (0%)	0 (0%)	0 (0%)	15 (54%)	0.0000001
<b>Acute confusional state</b>	23 (28%)	9 (30%)	0 (0%)	6 (40%)	8 (29%)	0.240
<b>Myelopathy</b>	12 (15%)	0 (0%)	5 (63%)	5 (33%)	2 (7%)	0.00002
<b>Movement disorder</b>	3 (4%)	0 (0%)	0 (0%)	0 (0%)	3 (11%)	0.117
<b>Cognitive dysfunction</b>	19 (23%)	8 (27%)	0 (0%)	5 (33%)	6 (21%)	0.320
<b>Mood disorder</b>	21 (26%)	14 (47%)	0 (0%)	2 (13%)	5 (18%)	0.008
<b>Anxiety disorder</b>	24 (30%)	14 (47%)	0 (0%)	4 (27%)	6 (21%)	0.037
<b>Psychosis</b>	26 (32%)	16 (53%)	0 (0%)	4 (27%)	6 (21%)	0.009



**Table 2. Biological, radiological characteristics, and treatments of patients with neuro-psychiatric systemic lupus erythematosus**

Abbreviations: APL, antiphospholipid antibodies; CTS, corticosteroids; dsDNA, double stranded desoxyribonucleic acid; HCQ, hydroxychloroquine; IV Ig, intravenous immunoglobulins; IS, immunosuppressive drug; MRI, magnetic resonance imaging.

	All (n=81)	Diffuse damage (n=30)	Focal damage (n=8)	Mixed damages (n=15)	Related to APL (n=28)	P
<b>Low C3 n (%)</b>	39/79 (49%)	19/29 (66%)	3/8 (38%)	6/14 (43%)	11/28 (39%)	0.183
<b>Positivity of anti-nuclear antibodies n(%)</b>	80/80 (100%)	30/30 (100%)	7/7 (100%)	15/15 (100%)	28/28 (100%)	/
<b>Positive dsDNA antibodies (radioimmunological assay) n (%)</b>	49/72 (68%)	18/28 (64%)	3/7 (43%)	10/15 (67%)	18/22 (82%)	0.245
<b>Positive dsDNA antibodies (ELISA assay) n(%)</b>	69/81 (85%)	25/30 (83%)	6/8 (75%)	14/15 (93%)	24/28 (86%)	0.674
<b>Positivity of anti-ribosomal P antibodies</b>	9/81 (11%)	4/30 (13%)	0/8 (0%)	2/15 (13%)	3/28 (11%)	0.746
<b>Positivity of APL</b>	27/80 (34%)	8/30 (27%)	2/8 (25%)	5/15 (33%)	12/27 (44%)	0.507
<b>Abnormal cerebrospinal fluid</b>	32/61 (52%)	7/23 (30%)	2/5 (40%)	12/15 (80%)	11/18 (61%)	0.020
<b>Abnormal brain MRI</b>	50/73 (68%)	17/27 (63%)	6/8 (75%)	7/11 (64%)	20/27 (74%)	0.789
<b>HCQ</b>	77/81 (95%)	30/30 (100%)	8/8 (100%)	14/15 (93%)	25/28 (89%)	0.255
<b>CTS</b>	74/81 (91%)	27/30 (90%)	7/8 (88%)	15/15 (100%)	25/28 (89%)	0.617
<b>With IS</b>	62/81 (77%)	24/30 (80%)	6/8 (75%)	11/15 (73%)	21/28 (75%)	0.954
<b>Alone</b>	11/81 (14%)	3/30 (10%)	1/8 (13%)	4/15 (27%)	3/28 (11%)	0.437
<b>Cyclophosphamide</b>	48/81 (59%)	22/30 (73%)	3/8 (38%)	7/15 (47%)	16/28 (57%)	0.167
<b>Mycophenolate mofetil</b>	36/81 (44%)	16/30 (53%)	3/8 (38%)	5/15 (33%)	12/28 (43%)	0.595
<b>Azathioprine</b>	21/81 (26%)	8/30 (27%)	4/8 (50%)	4/15 (27%)	5/28 (18%)	0.337
<b>Methotrexate</b>	1/81 (1%)	0/30 (0%)	0/8 (0%)	1/15 (7%)	0/28 (0%)	0.216
<b>IV Ig</b>	4/81 (5%)	1/30 (3%)	0/8 (0%)	2/15 (13%)	1/28 (4%)	0.400
<b>Plasma exchange</b>	18/81 (22%)	10/30 (33%)	1/8 (13%)	2/15 (13%)	5/28 (18%)	0.311
<b>Rituximab</b>	0/81 (0%)	0/30 (0%)	0/8 (0%)	0/15 (0%)	0/28 (0%)	/
<b>IS of renal impairment associated</b>	15/81 (19%)	9/30 (30%)	0/8 (0%)	1/15 (7%)	5/28 (18%)	0.119
<b>IS of neuro-psychiatric manifestation only</b>	59/81 (73%)	19/30 (63%)	7/8 (88%)	12/15 (80%)	21/28 (75%)	0.441

**Table 3. Treatments of central nervous system events**

Abbreviations: CTS, corticosteroids ; IV Ig, intravenous immunoglobulins.

	<b>Cerebrovascular disease (n=13)</b>	<b>Headache (n=28)</b>	<b>Seizure disorder (n=15)</b>	<b>Cognitive dysfunction (n=19)</b>	<b>Acute confusional state (n=20)</b>	<b>Aseptic meningitis (n=17)</b>
<b>CTS</b>	11 (85%)	24 (86%)	14 (93%)	19 (100%)	19 (95%)	17 (100%)
<b>Cyclophosphamide</b>	8 (62%)	17 (61%)	9 (60%)	17 (89%)	16 (80%)	9 (53%)
<b>Mycophenolate mofetil</b>	6 (46%)	13 (46%)	6 (40%)	12 (63%)	8 (40%)	7 (41%)
<b>Azathioprine</b>	2 (15%)	8 (29%)	2 (13%)	4 (21%)	4 (20%)	3 (18%)
<b>Methotrexate</b>	0 (0%)	1 (4%)	0 (0%)	0 (0%)	0 (0%)	1 (6%)
<b>IV Ig</b>	0 (0%)	1 (4%)	0 (0%)	1 (5%)	1 (5%)	1 (6%)
<b>Plasma exchange</b>	2 (15%)	8 (29%)	4 (27%)	5 (26%)	6 (30%)	4 (24%)
<b>Rituximab</b>	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	<b>Movement disorder (n=3)</b>	<b>Myelopathy (n=12)</b>	<b>Psychosis (n=26)</b>	<b>Demyelinative syndrome (n=1)</b>	<b>Anxiety disorder (n=24)</b>	<b>Mood disorder (n=22)</b>
<b>CTS</b>	3 (100%)	11 (92%)	24 (92%)	1 (100%)	20 (83%)	20 (91%)
<b>Cyclophosphamide</b>	1 (33%)	7 (58%)	20 (77%)	0 (0%)	19 (79%)	17 (77%)
<b>Mycophenolate mofetil</b>	1 (33%)	4 (33%)	16 (62%)	0 (0%)	14 (58%)	13 (59%)
<b>Azathioprine</b>	1 (33%)	5 (42%)	6 (23%)	1 (100%)	3 (13%)	5 (23%)
<b>Methotrexate</b>	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (5%)
<b>IV Ig</b>	1 (33%)	1 (8%)	1 (4%)	0 (0%)	1 (4%)	0 (0%)
<b>Plasma exchange</b>	0 (0%)	2 (17%)	11 (42%)	0 (0%)	6 (25%)	8 (36%)
<b>Rituximab</b>	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)

**Table 4. Outcomes of patients with neuro-psychiatric systemic lupus erythematosus**

Abbreviations: APL, antiphospholipid antibodies; NPSLE, Neuro-Psychiatric manifestations in Systemic Lupus Erythematosus.

	All (n=81)	Diffuse damage (n=30)	Focal damage (n=8)	Mixed damages (n=15)	Related to APL (n=28)	p
<b>Adverse events n (%)</b>	4/80 (5%)	2/30 (7%)	0/8 (0%)	1/15 (7%)	1/27 (4%)	0.854
<b>Infection</b>	3/80 (4%)	1/30 (3%)	0/8 (0%)	1/15 (7%)	1/27 (4%)	0.878
<b>Neuro-psychiatric relapse</b>	11/66 (17%)	3/26 (12%)	3/7 (43%)	3/13 (23%)	2/20 (10%)	0.174
<b>Neurological relapse</b>	9/66 (14%)	1/26 (4%)	3/7 (43%)	3/13 (23%)	2/20 (10%)	0.038
<b>Psychiatric relapse</b>	2/66 (3%)	2/26 (8%)	0/7 (0%)	0/13 (0%)	0/20 (0%)	0.366
<b>Only one relapse of NPSLE</b>	6/66 (9%)	2/26 (8%)	1/7 (14%)	2/13 (15%)	1/20 (5%)	0.725
<b>Two relapses of NPSLE</b>	2/66 (3%)	0/26 (0%)	1/7 (14%)	1/13 (8%)	0/20 (0%)	0.144
<b>At least three relapses of NPSLE</b>	3/66 (5%)	1/26 (4%)	1/7 (14%)	0/13 (0%)	1/20 (5%)	0.534
<b>Stay in intensive care</b>	18/81 (22%)	6/30 (20%)	0/8 (0%)	2/15 (13%)	10/28 (36%)	0.111
<b>Death</b>	2/49 (4%)	1/21 (5%)	0/6 (0%)	0/6 (0%)	1/16 (6%)	0.867
<b>Worsening outcome</b>	2/49 (4%)	1/21 (5%)	0/6 (0%)	0/6 (0%)	1/16 (6%)	0.867
<b>Improved outcome</b>	45/48 (94%)	19/20 (95%)	5/6 (83%)	6/6 (100%)	15/16 (94%)	0.667
<b>Neurological sequelae</b>	15/57 (26%)	4/21 (19%)	5/6 (83%)	2/11 (18%)	4/19 (21%)	0.010
<b>Inactive NPSLE after treatment</b>	42/47 (89%)	16/19 (84%)	6/6 (100%)	5/6 (83%)	15/16 (94%)	0.615
<b>Lost to follow-up</b>	32/81 (40%)	11/30 (37%)	2/8 (25%)	7/15 (47%)	12/28 (43%)	0.739

## Appendix

### 19 neuropsychiatric syndromes observed in systemic lupus erythematosus, ACR nomenclature of 1999

12 CNS syndromes	7 PNS syndromes
Aseptic meningitis	Acute inflammatory demyelinating polyradiculoneuropathy (Guillain-Barré syndrome)
Cerebrovascular disease	Autonomic disorder
Demyelinating syndrome	Mononeuropathy, single/multiplex
Headache (including migraine and benign intracranial hypertension)	Myasthenia gravis
Movement disorder (chorea)	Cranial neuropathy
Myelopathy	Plexopathy
Seizure disorders	Polyneuropathy
Acute confusional state	
Anxiety disorder	
Cognitive dysfunction	
Mood disorder	
Psychosis	

## References

1. Borchers A.T., Aoki C.A., Naguwa S.M., Keen C.L., Shoenfeld Y., Gershwin M.E. "Neuropsychiatric Features of Systemic Lupus Erythematosus." *Autoimmunity Reviews* 4, no. 6 (July 2005): 329–44.
2. Lefèvre G., Zéphir H., Michelin E., Semah F., Warembourg F., Pruvo J.-P., Hachulla E., et al. "[Neuropsychiatric systemic lupus erythematosus (2nd part). Diagnostic and treatment tools in psychiatric or central nervous system manifestations in systemic lupus erythematosus]." *La Revue De Medecine Interne* 33, no. 9 (September 2012): 503–13.
3. "The American College of Rheumatology Nomenclature and Case Definitions for Neuropsychiatric Lupus Syndromes." *Arthritis and Rheumatism* 42, no. 4 (April 1999): 599–608.
4. Hochberg M.C. "Updating the American College of Rheumatology Revised Criteria for the Classification of Systemic Lupus Erythematosus." *Arthritis and Rheumatism* 40, no. 9 (September 1997): 1725.
5. Petri M., Orbai A.-M., Alarcón G.S., Gordon C., Merrill J.T., Fortin P.R., Bruce I.N., et al. "Derivation and Validation of the Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic Lupus Erythematosus." *Arthritis and Rheumatism* 64, no. 8 (August 2012): 2677–86.
6. Thompson A.J., Banwell B.L., Barkhof F., Carroll W.M., Coetzee T., Comi G., Correale J., et al. "Diagnosis of Multiple Sclerosis: 2017 Revisions of the McDonald Criteria." *The Lancet. Neurology* 17, no. 2 (February 2018): 162–73.
7. Wingerchuk D.M., Banwell B., Bennett J.L., Cabre P., Carroll W., Chitnis T., de Seze J., et al. "International Consensus Diagnostic Criteria for Neuromyelitis Optica Spectrum Disorders." *Neurology* 85, no. 2 (July 14, 2015): 177–89.
8. Gladman D.D., Ibañez D., and Urowitz M.B. "Systemic Lupus Erythematosus Disease Activity Index 2000." *The Journal of Rheumatology* 29, no. 2 (February 2002): 288–91.
9. Hanly J.G., Kozora E., Beyea S., and Birnbaum J. "Nervous System Disease in Systemic Lupus Erythematosus: Current Status and Future Directions." *Arthritis & Rheumatology (Hoboken, N.J.)*, (in press).
10. Hanly J.G. "Diagnosis and Management of Neuropsychiatric SLE." *Nature Reviews. Rheumatology* 10, no. 6 (June 2014): 338–47.
11. DeGiorgio L.A., Konstantinov K.N., Lee S.C., Hardin J.A., Volpe B.T., and Diamond B. "A Subset of Lupus Anti-DNA Antibodies Cross-React with the NR2 Glutamate Receptor in Systemic Lupus Erythematosus." *Nature Medicine* 7, no. 11 (November 2001): 1189–93.
12. Govoni M., Bombardieri S., Bortoluzzi A., Caniatti L., Casu C., Conti F., De Vita S., et al. "Factors and Comorbidities Associated with First Neuropsychiatric Event in Systemic Lupus Erythematosus: Does a Risk Profile Exist? A Large Multicentre Retrospective Cross-Sectional Study on 959 Italian Patients." *Rheumatology (Oxford, England)* 51, no. 1 (January 2012): 157–68.
13. Hanly J.G., Urowitz M.B., Sanchez-Guerrero J., Bae S.C., Gordon C., Wallace D.J., Isenberg D., et al. "Neuropsychiatric Events at the Time of Diagnosis of Systemic Lupus Erythematosus: An International Inception Cohort Study." *Arthritis and Rheumatism* 56, no. 1 (January 2007): 265–73.
14. Lefèvre G., Zéphir H., Warembourg F., Michelin E., Pruvo J.-P., Hachulla E., Semah F., et al. "[Neuropsychiatric systemic lupus erythematosus (1st part). Cases definitions and diagnosis and treatment of central nervous system and psychiatric manifestations of systemic lupus erythematosus]." *La Revue De Medecine Interne* 33, no. 9 (September 2012): 491–502.

15. Unterman A., Nolte J.E.S., Boaz M., Abady M., Shoenfeld Y., and Zandman-Goddard G.. “Neuropsychiatric Syndromes in Systemic Lupus Erythematosus: A Meta-Analysis.” *Seminars in Arthritis and Rheumatism* 41, no. 1 (August 2011): 1–11.
16. Sfikakis P.P., Mitsikostas D.D., Manoussakis M.N., Foukaneli D., and Moutsopoulos H.M. “Headache in Systemic Lupus Erythematosus: A Controlled Study.” *British Journal of Rheumatology* 37, no. 3 (March 1998): 300–303.
17. Davey R., Bamford J., and Emery P. “The ACR Classification Criteria for Headache Disorders in SLE Fail to Classify Certain Prevalent Headache Types.” *Cephalalgia: An International Journal of Headache* 28, no. 3 (March 2008): 296–99.
18. Mitsikostas D.D., Sfikakis P.P., and Goadsby P.J. “A Meta-Analysis for Headache in Systemic Lupus Erythematosus: The Evidence and the Myth.” *Brain: A Journal of Neurology* 127, no. Pt 5 (May 2004): 1200–1209.
19. Bertias G.K., Ioannidis J.P.A., Aringer M., Bollen E., Bombardieri S., Bruce I.N., Cervera R., et al. “EULAR Recommendations for the Management of Systemic Lupus Erythematosus with Neuropsychiatric Manifestations: Report of a Task Force of the EULAR Standing Committee for Clinical Affairs.” *Annals of the Rheumatic Diseases* 69, no. 12 (December 2010): 2074–82.
20. Mok C.C., Lau C.S., and Wong R.W. “Neuropsychiatric Manifestations and Their Clinical Associations in Southern Chinese Patients with Systemic Lupus Erythematosus.” *The Journal of Rheumatology* 28, no. 4 (April 2001): 766–71.
21. Harboe E., Tjensvoll A.B., Maroni S., Gøransson L.G., Greve O.J., Beyer M.K., Herigstad A., Kvaløy J.T., and Omdal R. “Neuropsychiatric Syndromes in Patients with Systemic Lupus Erythematosus and Primary Sjögren Syndrome: A Comparative Population-Based Study.” *Annals of the Rheumatic Diseases* 68, no. 10 (October 2009): 1541–46.
22. Hanly J.G., Urowitz M.B., Su L., Bae S.-C., Gordon C., Clarke A., Bernatsky S., et al. “Autoantibodies as Biomarkers for the Prediction of Neuropsychiatric Events in Systemic Lupus Erythematosus.” *Annals of the Rheumatic Diseases* 70, no. 10 (October 2011): 1726–32.
23. Hanly J.G., Urowitz M.B., Siannis F., Farewell V., Gordon C., Bae S.C., Isenberg D., et al. “Autoantibodies and Neuropsychiatric Events at the Time of Systemic Lupus Erythematosus Diagnosis: Results from an International Inception Cohort Study.” *Arthritis and Rheumatism* 58, no. 3 (March 2008): 843–53.
24. Ainala H., Hietaharju A., Loukkola J., Peltola J., Korpela M., Metsänoja R., and Auvinen A. “Validity of the New American College of Rheumatology Criteria for Neuropsychiatric Lupus Syndromes: A Population-Based Evaluation.” *Arthritis and Rheumatism* 45, no. 5 (October 2001): 419–23.
25. Bortoluzzi A., Scirè C.A., Bombardieri S., Caniatti L., Conti F., De Vita S., Doria A., et al. “Development and Validation of a New Algorithm for Attribution of Neuropsychiatric Events in Systemic Lupus Erythematosus.” *Rheumatology (Oxford, England)* 54, no. 5 (May 2015): 891–98.
26. Cotton F., Bouffard-Vercelli J., Hermier M., Tebib J., Vital Durand D., Tran Minh V.A., and Rousset H. “[MRI of central nervous system in a series of 58 systemic lupus erythematosus (SLE) patients with or without overt neuropsychiatric manifestations].” *La Revue De Medecine Interne* 25, no. 1 (January 2004): 8–15.
27. Nived O., Sturfelt, Liang M.H., and De Pablo P.. “The ACR Nomenclature for CNS Lupus Revisited.” *Lupus* 12, no. 12 (2003): 872–76.
28. Sciascia S., Bertolaccini M.L., Baldovino S., Roccatello D., Khamashta M.A., and Sanna G. “Central Nervous System Involvement in Systemic Lupus Erythematosus: Overview on Classification Criteria.” *Autoimmunity Reviews* 12, no. 3 (January 2013): 426–29.

29. Netto T.M., Zimmermann N., Rueda-Lopes F., Bizzo B.C., Fonseca R.P., and Gasparetto E.L. “Neuropsychiatric Lupus: Classification Criteria in Neuroimaging Studies.” *The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques* 40, no. 3 (May 2013): 284–91.
30. Postal M., Tamires Lapa A., Reis F., Rittner L., and Appenzeller S. “Magnetic Resonance Imaging in Neuropsychiatric Systemic Lupus Erythematosus: Current State of the Art and Novel Approaches.” *Lupus* 26, no. 5 (April 2017): 517–21.
31. Hanly J. G., Urowitz M.B., Su L., Sanchez-Guerrero J., Bae S.C., Gordon C., Wallace D.J., et al. “Short-Term Outcome of Neuropsychiatric Events in Systemic Lupus Erythematosus upon Enrollment into an International Inception Cohort Study.” *Arthritis and Rheumatism* 59, no. 5 (May 15, 2008): 721–29.
32. Fernandes Moça Trevisani V., Castro A.A., Ferreira Neves Neto J., and Atallah A.N. “Cyclophosphamide versus Methylprednisolone for Treating Neuropsychiatric Involvement in Systemic Lupus Erythematosus.” *The Cochrane Database of Systematic Reviews*, no. 2 (February 28, 2013): CD002265.
33. Barile-Fabris L., Ariza-Andraca R., Olguín-Ortega L., Jara L.J., Fraga-Mouret A., Miranda-Limón J.M., Fuentes de la Mata J., Clark P., Vargas F., and Alocer-Varela J. “Controlled Clinical Trial of IV Cyclophosphamide versus IV Methylprednisolone in Severe Neurological Manifestations in Systemic Lupus Erythematosus.” *Annals of the Rheumatic Diseases* 64, no. 4 (April 2005): 620–25.
34. Stojanovich L., Stojanovich R., Kostich V., and Dzijlich E. “Neuropsychiatric Lupus Favourable Response to Low Dose I.v. Cyclophosphamide and Prednisolone (Pilot Study).” *Lupus* 12, no. 1 (2003): 3–7.
35. Marra D., Amoura Z., Soussan N., Haroche J., Consoli A., Ghillami-Dalbin P., Diemert M.-C., Musset L., Piette J.-C., and Cohen D. “Plasma Exchange in Patients with Stuporous Catatonia and Systemic Lupus Erythematosus.” *Psychotherapy and Psychosomatics* 77, no. 3 (2008): 195–96.

## Serment d'Hippocrate

Au moment d'être admise à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité.

Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux, individuels et sociaux.

Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité. Même sous la contrainte, je ne ferai pas usage de mes connaissances contre les lois de l'humanité.

J'informerai les patients des décisions envisagées, de leurs raisons et de leurs conséquences.

Je ne tromperai jamais leur confiance et n'exploiterai pas le pouvoir hérité des circonstances pour forcer les consciences.

Je donnerai mes soins à l'indigent et à quiconque me les demandera. Je ne me laisserai pas influencer par la soif du gain ou la recherche de la gloire.

Admise dans l'intimité des personnes, je tairai les secrets qui me seront confiés. Reçue à l'intérieur des maisons, je respecterai les secrets des foyers et ma conduite ne servira pas à corrompre les mœurs.

Je ferai tout pour soulager les souffrances. Je ne prolongerai pas abusivement les agonies. Je ne provoquerai jamais la mort délibérément.

Je préserverai l'indépendance nécessaire à l'accomplissement de ma mission. Je n'entreprendrai rien qui dépasse mes compétences. Je les entretiendrai et les perfectionnerai pour assurer au mieux les services qui me seront demandés.

J'apporterai mon aide à mes confrères ainsi qu'à leurs familles dans l'adversité.

Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses ; que je sois déshonorée et méprisée si j'y manque.